Paula and Rodger Riney Foundation
EIN 823268996About
THE FOUNDATION'S START-UP PERIOD IS 2018-2021. AS OF 12/31/20, THE FOUNDATION'S START-UP PERIOD DISTRIBUTABLE AND MINIMUM AMOUNTS WERE: 2018 $ 890,859 X 20% = $ 178,172 2019 $8,200,014 X 40% = $ 3,280,006 2020 $8,108,508 X 60% = $ 4,865,105 2021 $6,917,393 X 80% = $ 5,533,914 (PER ON 2020 990PF) TOTAL $13,857,197START-UP PERIOD MINIMUM AMOUNTS MUST BE DISTRIBUTED BEFORE THE END OF THE START-UP PERIOD, BUT THERE IS NOT A REQUREIMENT THAT ANY PORTION OF SUCH AMOUNT BE DISTRIBUTED IN ANY ONE TAXABLE YEAR OF THE START-UP PERIOD. THE FOUNDATION'S ACTUAL PAYMENTS MADE IN CASH FOR EXEMPT PURPOSES DURING THE START-UP PERIOD ARE AS FOLLOWS: 2018 $ 1,017,000 2019 $ 9,045,023 2020 $ 5,642,045 TOTAL $15,704,068 THE FOUNDATION'S ACTUAL DISTRIBUTED AMOUNT EXCEEDS THE START-UP PERIOD MINIMUM AMOUNT. TREAS. REG. 53.4942(A)-3(B)(3) AND (4) PROVIDE THE CASH-DISTRIBUTION TEST AND START-UP PERIOD GUIDANCE, RESPECTIVELY. THE FOUNDATION HAS MET THE ACTUAL DISTRIBUTION REQUIREMENT FOR THE START-UP PERIOD. THE FOUNDATION DESIRES TO FUND A PROJECT WHICH WILL FURTHER RESEARCH IN, ADVANCE THE SEARCH FOR CURES FOR, AND ENHANCE THE PREVENTION OF MULTIPLE MYELOMA. THE SPECIFIC PROJECT WOULD NOT BE COMPLETED BY THE END OF THE TAXABLE YEAR IN WHICH THE SET-ASIDE WAS TO BE MADE (2020). THE AMOUNT SET-ASIDE FOR THIS PROJECT IS ANTICIPATED TO BE ACTUALLY PAID WITHIN A TWELVE MONTH PERIOD, BUT NO MORE THAN 60 MONTHS AFTER THE DATE OF THE SET-ASIDE.
Focus Areas
Application Information
Financial Trends
Giving Over Time
Total Assets Over Time
View financial data as table
| Year | Total Giving | Total Assets | Revenue | Grants |
|---|---|---|---|---|
| 2018 | $1.0M | $163.1M | $2.2M | 19 |
| 2019 | N/A | $171.9M | $3.8M | N/A |
| 2020 | $5.0M | $212.6M | $3.5M | 3 |
| 2021 | $17.2M | $228.3M | $1.8M | 4 |
| 2022 | $30.7M | $166.4M | $17.5M | 6 |
| 2023 | $42.5M | $154.5M | $23.9M | 25 |
| 2024 | $32.7M | $149.7M | $3.2M | 14 |
Grant Size Distribution
Based on 71 grants on record
Geographic Distribution
Officers & Directors
Grants Awarded (71 total)
| Purpose | ||||
|---|---|---|---|---|
| Dana Farber Cancer Institute | Boston, MA | $16,000,000 | ADVANCE TREATMENT, CURE AND PREVENTION OF CANCER AND RELATED DISEASES | 2022 |
| Dana Farber Cancer Institute | Boston, MA | $13,527,778 | ADVANCE TREATMENT, CURE AND PREVENTION OF CANCER AND RELATED DISEASES | 2023 |
| Dana Farber Cancer Institute | Boston, MA | $12,000,000 | ADVANCE TREATMENT, CURE AND PREVENTION OF CANCER AND RELATED DISEASES | 2024 |
| Inserm | Paris Cedex, None | $5,150,000 | ADVANCE TREATMENT, CURE AND PREVENTION OF CANCER AND RELATED DISEASES | 2021 |
| Centre Hospitalier Universitaire De Toulouse | Toulouse, None | $5,150,000 | ADVANCE TREATMENT, CURE AND PREVENTION OF CANCER AND RELATED DISEASES | 2024 |
| University of Wurzburg | Wurzberg, None | $5,139,720 | ADVANCE TREATMENT, CURE AND PREVENTION OF CANCER AND RELATED DISEASES | 2023 |
| Dana Farber Cancer Institute | Boston, MA | $5,100,000 | ADVANCE TREATMENT, CURE AND PREVENTION OF CANCER AND RELATED DISEASES | 2021 |
| Dana Farber Cancer Institute | Boston, MA | $5,000,000 | ADVANCE TREATMENT, CURE, AND PREVENTION OF CANCER AND RELATED DISEASES | 2020 |
| University of Missouri | Columbia, MO | $4,110,826 | ADVANCE TREATMENT, CURE AND PREVENTION OF CANCER AND RELATED DISEASES | 2024 |
| St Louis Community Foundation | St Louis, MO | $4,100,000 | PLEASE SEE PART XIV 3A FOR THE PURPOSE OF THE CONTRIBUTIONTHE CURRENT YEAR CONTRIBUTION WAS PROVIDED TO ADMINISTER... | 2023 |
| University of Navarra | Pamplona, None | $3,537,000 | ADVANCE TREATMENT, CURE AND PREVENTION OF CANCER AND RELATED DISEASES | 2021 |
| American Friends of Uhn | Toronto, None | $3,481,965 | ADVANCE TREATMENT, CURE AND PREVENTION OF CANCER AND RELATED DISEASES | 2022 |
| Princess Margarate Cancer Foundation (University Health Network) | Toronto, None | $3,481,964 | ADVANCE TREATMENT, CURE AND PREVENTION OF CANCER AND RELATED DISEASES | 2023 |
| International Myeloma Society | Rochester, MN | $3,426,527 | ADVANCE TREATMENT, CURE AND PREVENTION OF CANCER AND RELATED DISEASES | 2021 |
| International Myeloma Society | Needham, MA | $3,366,379 | ADVANCE TREATMENT, CURE AND PREVENTION OF CANCER AND RELATED DISEASES | 2023 |
| International Myeloma Society | Needham, MA | $3,243,663 | ADVANCE TREATMENT, CURE AND PREVENTION OF CANCER AND RELATED DISEASES | 2022 |
| International Myeloma Society | Boston, MA | $3,139,644 | ADVANCE TREATMENT, CURE AND PREVENTION OF CANCER AND RELATED DISEASES | 2024 |
| Massachusetts General Hospital | Boston, MA | $2,991,261 | ADVANCE TREATMENT, CURE AND PREVENTION OF CANCER AND RELATED DISEASES | 2023 |
| The Medical College of Wisconsin | Milwaukee, WI | $2,982,559 | ADVANCE TREATMENT, CURE AND PREVENTION OF CANCER AND RELATED DISEASES | 2022 |
| The Medical College of Wisconsin | Milwaukee, WI | $2,982,559 | ADVANCE TREATMENT, CURE AND PREVENTION OF CANCER AND RELATED DISEASES | 2023 |
| Massachusetts General Hospital | Boston, MA | $2,813,974 | ADVANCE TREATMENT, CURE AND PREVENTION OF CANCER AND RELATED DISEASES | 2022 |
| Purdue University | West Lafayette, IN | $2,131,435 | ADVANCE TREATMENT, CURE AND PREVENTION OF CANCER AND RELATED DISEASES | 2022 |
| Purdue University | West Lafayette, IN | $2,131,435 | ADVANCE TREATMENT, CURE AND PREVENTION OF CANCER AND RELATED DISEASES | 2023 |
| Mayo Clinic | Rochester, MN | $2,019,000 | ADVANCE TREATMENT, CURE AND PREVENTION OF CANCER AND RELATED DISEASES | 2024 |
| Ohio State University Comprehensive Cancer Center | Columbus, OH | $2,000,000 | ADVANCE TREATMENT, CURE AND PREVENTION OF CANCER AND RELATED DISEASES | 2023 |